Merck KGaA's recently approved MS pill Mavenclad (cladribine) is also available to NHS patients after the company agreed to only charge for patients that respond to the treatment.

Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF ...